Thursday’s Midday Movers: Rosetta Genomics Ltd (ROSG), Gastar Exploration (GST), MannKind (MNKD), Cytori Therap (CYTX), Anthera Pharmaceuticals (ANTH)

By Carrie Williams

So far Thursday, February 15, NASDAQ is down -0.99% and the S&P is down -0.66%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Rosetta Genomics Ltd (NASDAQ:ROSG), Gastar Exploration (NYSE MKT:GST), MannKind (NASDAQ:MNKD), Cytori Therap (NASDAQ:CYTX) and Anthera Pharmaceuticals (NASDAQ:ANTH).

Rosetta Genomics Ltd is down -14.53% in midday trading to $0.47. Shares opened today at $0.55. The company has a 52-week low of $0.42 and a 52-week high of $6.10.

Gastar Exploration is down -13.68% in midday trading to $0.82. Shares opened today at $0.95. The company has a 52-week low of $0.38 and a 52-week high of $2.19. On the Street’s front, the average 12-month analyst price target for the stock is $1.38, marking a 45.26% potential upside from current levels. In a report released today, Williams Capital Group analyst Gabriele Sorbara reiterated a Hold rating on GST, with a price target of $1.25, which implies an upside of 32% from current levels. In the last 30 days, insiders have sold $253.4K worth of GST shares.

MannKind is down -11.71% in midday trading to $2.94. Shares opened today at $3.33. The company has a 52-week low of $0.67 and a 52-week high of $6.96. Over the last 3 months, the insider sentiment on MannKind has been positive based on 16 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Cytori Therap is down -8.81% in midday trading to $0.33. Shares opened today at $0.36. The company has a 52-week low of $0.22 and a 52-week high of $2.08. On the Street’s front, the average 12-month analyst price target for the stock is $4, marking a 1011.11% potential upside from current levels. In a report issued on February 13, Maxim Group analyst Jason Kolbert assigned a Buy rating on CYTX, with a price target of $4, which implies an upside of 1011% from current levels. In the last 30 days, insiders have sold $169.3K worth of CYTX shares. Over the last 3 months, the insider sentiment on Cytori Therap has been negative based on 3 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Anthera Pharmaceuticals is down -7.69% in midday trading to $1.68. Shares opened today at $1.82. The company has a 52-week low of $1.20 and a 52-week high of $6.24. On the Street’s front, the average 12-month analyst price target for the stock is $2.88, marking a 58.24% potential upside from current levels. In a report issued on February 13, Jefferies Co. analyst Matthew Andrews reiterated a Hold rating on ANTH, with a price target of $1.75, which represents a slight downside potential from current levels. Separately, on January 22, Piper Jaffray’s Edward Tenthoff reiterated a Buy rating on the stock and has a price target of $4.